Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03797326
Title Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

ovarian cancer

colorectal cancer

stomach cancer

cholangiocarcinoma

gallbladder cancer

triple-receptor negative breast cancer

glioblastoma

Advanced Solid Tumor

Therapies

Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.